Bank of America Securities analyst Kevin Fischbeck reiterated a Sell rating on Clover Health Investments (CLOV – Research Report) yesterday and set a price target of $0.90. The company’s shares closed yesterday at $1.39.
Fischbeck covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Cigna, and Molina Healthcare. According to TipRanks, Fischbeck has an average return of 1.4% and a 56.90% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Clover Health Investments with a $0.95 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.50 and a one-year low of $0.71. Currently, Clover Health Investments has an average volume of 9.59M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clover Health Investments Corp is a healthcare technology company. It uses its proprietary technology platform to collect, structure, and analyze health and behavioral data to improve medical outcomes and lower costs for patients.
Read More on CLOV:
- Clover Health sees FY23 insurance revenue $1.2B-$1.23B
- Clover Health reports Q2 revenue $513.628M, consensus $490.82M
- Clover Health Reports Strong Second Quarter 2023 Results; Highlights Improved Financial Performance and Guidance Ranges
- Clover Health options imply 16.3% move in share price post-earnings
- Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement
